Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent

Why It Matters

The new oral GLP‑1 expands Lilly’s market share and reinforces its pricing power, accelerating the shift toward convenient obesity therapies. This puts pressure on Novo Nordisk, which must counter with its own oral products and fend off generic competition.

Key Takeaways

• Lilly Q1 revenue rose 56% YoY to nearly $20 billion
• Foundayo approved as first unrestricted oral GLP‑1 for obesity
• GLP‑1 sales contributed $12.8 billion, boosting EPS to $8.55
• Lilly raised 2026 revenue guide to $82‑$85 billion
• Novo faces generic Ozempic risk and pending oral competition

Pulse Analysis

The global GLP‑1 agonist market, now valued at roughly $63 billion, is on track to triple over the next decade as obesity and type‑2 diabetes treatments gain prominence. Investors view the space as a growth engine, with the two dominant players, Eli Lilly and Novo Nordisk, racing to capture share through innovative delivery methods. While injectable options have set the standard, oral formulations promise broader patient adoption, especially among those averse to needles, positioning the sector for sustained expansion.

Lilly’s Q1 2026 results underscore its momentum. A 56% revenue surge, propelled by $12.8 billion in GLP‑1 sales, lifted total earnings per share to $8.55, well above expectations. The FDA’s clearance of Foundayo—an oral GLP‑1 without food or water timing constraints—adds a differentiated product to Lilly’s portfolio, potentially making it the preferred therapy for obesity. Early uptake among the first 20,000 patients suggests rapid market penetration, and the company’s revised full‑year guidance of $82‑$85 billion signals confidence in sustained demand.

For Novo Nordisk, the landscape becomes more challenging. The Danish firm must accelerate its own oral Ozempic program and defend against generic entrants, such as Canada’s newly approved Ozempic copy. While Novo continues to explore non‑incretin obesity candidates, the immediate pressure lies in matching Lilly’s convenience advantage. Analysts remain split, but the broader implication is a heightened competitive race that could drive further innovation, pricing dynamics, and consolidation in the lucrative GLP‑1 arena.